<DOC>
	<DOC>NCT01461850</DOC>
	<brief_summary>Patients with advanced ovarian cancer (FIGO stage III C) and highly disseminated tumor will be randomized into two arms: primary debulking surgery followed by adjuvant chemotherapy vs. neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The primary end point is the evaluation and comparison of the surgical complications of primary surgery and IDS and the evaluation of the progression free survival (PFS)</brief_summary>
	<brief_title>Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients with suspected advanced ovarian cancer (FIGO stage IIIC) PIV ≥ 8, PIV ≤ 12 Estimated life expectancy of at least 4 weeks. PS ≤ 2 Appropriate respiratory, hepatic, cardiological, bone marrow and renal functions (Creatinine Clearance &gt; 60 mL/min according to Cockcroft formula) Patient capable of consent. Pregnancy or breastfeeding. Nonappropriate respiratory, hepatic, cardiological, bone marrow and renal functions Large size mass reaching the xiphoid, occupying all the abdominal cavity and/or infiltrating the abdominal wall. Mesenteric retraction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>